<DOC>
	<DOCNO>NCT00379678</DOCNO>
	<brief_summary>THe study seek determine pimecrolimus positive effect increase antimicrobial peptide expression reduce vaccinia virus growth skin explants patient atopic dermatitis .</brief_summary>
	<brief_title>Effects Pimecrolimus Skin Biopsy Ex-plants From Patients With Atopic Dermatitis</brief_title>
	<detailed_description>AMP play important role innate immune response infection . Two major class AMP identify : beta defensins ( HBD ) ( Harder 1997 ) cathelicidins ( LL-37 ) ( Gallo 2002 ) . AMP show antibacterial activity S. aureus ( Ong 2002 ) antiviral activity vaccinia virus ( VV ) ( Howell 2004 ) . The skin AD patient characterized deficiency AMP , may account propensity skin infection ( Ong 2002 ) . This AMP deficiency believe due increase Th2 cytokine , IL-4 IL-13 , expression ( Ong 2002 ) , well increase IL-10 expression ( Howell 2005 ) . Other cytokine know affect AMP expression TNF-alpha ( TNFa ) , IL-6 , IL-1 interferon-gamma ( IFN-g ) . These cytokine induce expression AMP ( Erdag 2002 , Liu 2002 , Ong 2002 , Nomura 2003 ) . However , negligible level TNF-a IFN-g show AD skin possibly due downregulation Th2 cytokine ( Nomura 2003 ) . Therefore , neutralization IL-4 , IL-13 IL-10 AD patient may correct AMP deficiency AD patient decrease propensity recurrent skin infection . Interestingly , addition anti-IL10 skin explants AD patient augment HBD-2 LL-37 expression ( Howell 2005 ) . In addition , IL-4 IL-13 find enhance VV replication down-regulate LL-37 VV-stimulated keratinocytes neutralization IL-4/IL-13 AD skin augment LL-37 inhibit VV replication ( Howell 2006a ) . LL-37 HBD-3 found kill VV ( Howell 2004 ; Howell 2006b ) . Thus deficiency AMP may contribute increased propensity viral infection . Therapeutic strategy need augment AMP expression AD skin reduce skin infection . Pimecrolimus calcineurin inhibitor bind high affinity macrophilin-12 . The complex pimecrolimus-macrophilin inhibits calcineurin , phosphatase require dephosphorylation cytosolic form nuclear factor activate T cell ( NF-AT ) . As consequence , pimecrolimus prevents nuclear translocation NFAT thereby transcription release Th1 Th2 cytokines IL-2 , IFN-g , IL-4 , IL-5 , IL-10 , TNF-a GM-CSF ( Grassberger 1999 ) . As common topical corticosteroid treatment use AD patient , triamcinolone diacetate include study active comparator .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<criteria>Has sign inform consent form Male female race ethnicity Patient 18 year age older active AD Active AD severity define accord Hanifin Rajka clinical criterion ( Hanifin , J.M. , Rajka , G. 1980 ) Chronic AD one year duration Patients AD face Women childbearing potential use contraception method ( ) specify study ( abstinence , oral contraceptive , IUD , diaphragm ) , well woman breastfeed Patients severe medical condition ( ) view investigator prohibit participation study Use investigational agent last 30 day Patient pregnant lactating Patient use oral corticosteroid , systemic immunosuppressive , immunomodulary medication within last 28 day Patient receive immunotherapy within last year Patient history bleed disorder Use aspirin , oral antihistamine , oral antibiotic , oral cyclosporine , topical medication within seven day Screening/Baseline Visit include ( restrict ) , Elidel , Protopic , topical corticosteroid , topical antibiotic Patients know lidocaine allergy Inability patient follow study procedure document history patient noncompliant Any concomitant diagnosis , opinion investigator , might impact biopsy procedure Infected AD Use topical medication &lt; 7 day systemic medication &lt; one month prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>atopic dermatitis</keyword>
</DOC>